US 12187792
IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 12187792 (IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 40
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K40/36